Scarica l'app Stockscreener
12.25
4.74%
-0.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.86
Aprire:
$12.81
Volume 24 ore:
1.71M
Relative Volume:
1.44
Capitalizzazione di mercato:
$1.03B
Reddito:
$7.62M
Utile/perdita netta:
$-271.60M
Rapporto P/E:
-3.4982
EPS:
-3.5018
Flusso di cassa netto:
$-271.54M
1 W Prestazione:
+0.49%
1M Prestazione:
-14.34%
6M Prestazione:
-9.39%
1 anno Prestazione:
+24.75%
Intervallo 1D:
$12.04
$12.83
Intervallo di 1 settimana:
$11.55
$13.03
Portata 52W:
$9.40
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
12.25 | 1.04B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
U.S. cracks down on EyePoint over alleged kickbacks, company to pay $4.66 million settlement - Peoples Gazette Nigeria
Did EyePoint's (EYPT) Federal Settlement and 5‑Year Integrity Deal Just Reframe Its Risk Profile? - simplywall.st
EYPT|EyePoint Pharmaceuticals Inc|Price:12.405|Chg%:+0.215 - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EyePoint Pharmaceuticals Inc - TradingKey
EyePoint, Inc. Revenue Breakdown – NASDAQ:EYPT - TradingView
EyePoint Pharmaceuticals Inc (EYPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
EYPT|EyePoint Pharmaceuticals Inc|Price:12.190|Chg%:-0.280 - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RBC Capital Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
J.P. Morgan Maintains EyePoint(EYPT.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
EYPT (NASDAQ: EYPT) plans sale of 1,235 common shares from options - Stock Titan
EYPT (NASDAQ: EYPT) affiliate plans sale of 1,235 common shares via Form 144 - Stock Titan
Form 144 EyePoint For: 21 July By Investing.com - Investing.com South Africa
EYPT (NASDAQ: EYPT) plans brokered sale of 421,235 shares valued at $5.5M - Stock Titan
Price to earnings forward of EyePoint, Inc. – MUN:PV3B - TradingView
Drug company to pay $4.7M after admitting it paid providers to use its product - Yahoo Finance
Watertown Company Will Pay Nearly $4.7 Million to Resolve False Claims Act Allegations - watertownmanews.com
EyePoint to pay $4.6M to settle with DOJ over kickback claims - MSN
EyePoint Pharmaceuticals Agrees to Pay $4.6 Million to Settle False Claims Act Allegations - Markets Herald
EyePoint, Inc. Settles DOJ False Claims Act Case and Implements Comprehensive Compliance Program - Minichart
Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily
EyePoint Pharmaceuticals Agrees to Settle US False Claims Act Allegations - Moomoo
EyePoint to Pay $4.7M to Resolve Allegations of False Claims Act Violations - Moomoo
Eyepoint Enters Settlement Agreement With DOJ, OIG-HHS, And DHASEC Filing - TradingView
EyePoint Pharmaceuticals (EYPT) Settles for $4.6M Over Kickback Allegations - GuruFocus
EyePoint (NASDAQ: EYPT) signs five-year federal Corporate Integrity Agreement - Stock Titan
United States: EyePoint Pharmaceuticals To Pay $4.6 Million To Resolve False Claims Act Allegations - The St Kitts Nevis Observer
EyePoint Agrees To Pay $4.65M To U.S. Government In FCA Suit Settlement - Mealey's
EyePoint to pay $4.6M to settle with DoJ over kickback claims - Seeking Alpha
Stifel Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
EYPT Initiated Coverage by Stifel -- Buy Rating with $40 Price T - GuruFocus
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Two New EyePoint Employees Receive Options for 63,500 Shares - Stock Titan
Stifel initiates EyePoint stock with buy rating on retinal drug potential By Investing.com - Investing.com South Africa
Stifel initiates EyePoint stock with buy rating on retinal drug potential - Investing.com Nigeria
Stifel Initiates EyePoint(EYPT.US) With Buy Rating, Announces Target Price $40 - Moomoo
EyePoint, Inc. (EYPT) CEO exercises RSUs, with shares withheld for taxes - Stock Titan
Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
EyePoint Names Tarek S. Hassan, MD, as SVP and Chief Strategic Science Officer - VisionMonday.com
Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
EyePoint Appoints Retina Specialist Tarek S. Hassan as Chief Strategic Science Officer - citybiz
EyePoint Appoints Retina Specialist Dr. Tarek S. Hassan as Chief Strategic Science Officer - Quiver Quantitative
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer - marketscreener.com
Renowned retina specialist Tarek S. Hassan joins EyePoint ahead of key DURAVYU trial readout - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Eyepoint Inc Azioni (EYPT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Duker Jay S. | President and CEO |
Jul 10 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
17,653 |
| Ribeiro Ramiro | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
8.26 |
4,875 |
40,268 |
4,875 |
| Ribeiro Ramiro | Chief Medical Officer |
Jun 30 '26 |
Sale |
15.01 |
4,875 |
73,167 |
0 |
| Elston George | Chief Financial Officer |
May 25 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
95,318 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Option Exercise |
8.26 |
2,437 |
20,130 |
2,437 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Sale |
15.00 |
2,437 |
36,555 |
0 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):